Beam Therapeutics and Prime Medicine are competing for market share in the AATD gene-editing space, with an arbitration ruling favoring Prime's program.
1 report, 1 independent
Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Beam Therapeutics and Prime Medicine are competing for market share in the AATD gene-editing space, with an arbitration ruling favoring Prime's program.